CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Valganciclovir

缬更昔洛韦 杂质对照品Valganciclovir Impurities

EP32 个杂质条目32 impurity entries

本页汇总 缬更昔洛韦 的 32 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 32 impurity reference standards of Valganciclovir with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 缬更昔洛韦(Valganciclovir)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 分析方法Analytical MethodsA novel liquid chromatography with quadrupole time-of-flight-tandem mass spectroscopy method for ultra-trace level identification and quantification of the genotoxic impurity 2,6-diamino-5-nitropyrimidin-4(3H)-one in valganciclovir hydrochloride
    Biomedical chromatography : BMC · 2024 · Ali SM et al.  ·  PMID 38072000  ·  DOI
  2. 分析方法Analytical MethodsSustainable RP-HPLC Method Development Using AQbD Approach for Simultaneous Estimation of Valganciclovir Hydrochloride and Piperine-Loaded Lipid Nanoparticles
    Biomedical chromatography : BMC · 2026 · Mahalkari A et al.  ·  PMID 41980886  ·  DOI
  3. 分析方法Analytical MethodsSimultaneous LC-MS/MS method for the quantification of 5-flucytosine, ganciclovir, and valganciclovir to support combined prodrug-activated gene therapy
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2026 · Lee YH et al.  ·  PMID 41967452  ·  DOI
  4. 分析方法Analytical MethodsDevelopment of non-aqueous titrimetric and spectrophotometric methods for the determination of valganciclovir hydrochloride in bulk drug and tablets
    Annales pharmaceutiques francaises · 2021 · Abdulrahman SAM et al.  ·  PMID 33548279  ·  DOI
  5. 分析方法Analytical MethodsA sensitive assay for simultaneous determination of plasma concentrations of valganciclovir and its active metabolite ganciclovir by LC/MS/MS
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2007 · Xu HR et al.  ·  PMID 17126086  ·  DOI

缬更昔洛韦 —— 原料药与杂质对照品Valganciclovir — drug substance & impurities

共 32 个条目(含原料药本体)32 items incl. the drug substance
Valganciclovir Impurity 3 (Valganciclovir Hydrochloride EP Impurity C) structure
EPC
缬更昔洛韦杂质3 (盐酸缬更昔洛韦EP杂质C)Valganciclovir Impurity 3 (Valganciclovir Hydrochloride EP Impurity C)
Valganciclovir Impurity 3 (Valganciclovir Hydrochloride EP Impurity C)
CAS No.1202645-50-8
Chemical FormulaC7H9N5O2
Purity>95%询价On request
10mg25mg50mg100mg
Valganciclovir Impurity 18 Monomer (Valganciclovir Hydrochloride EP Impurity D) structure
EPD
缬更昔洛韦杂质18 单体 (盐酸缬更昔洛韦EP杂质D)Valganciclovir Impurity 18 Monomer (Valganciclovir Hydrochloride EP Impurity D)
Valganciclovir Impurity 18 Monomer (Valganciclovir Hydrochloride EP Impurity D)
CAS No.1219792-42-3
Chemical FormulaC14H22N6O5
Purity>95%询价On request
10mg25mg50mg100mg
Valganciclovir Impurity 18 (Valganciclovir Hydrochloride EP Impurity D Hydrochloride) structure
EPD
缬更昔洛韦杂质18 (盐酸缬更昔洛韦EP杂质D 盐酸盐)Valganciclovir Impurity 18 (Valganciclovir Hydrochloride EP Impurity D Hydrochloride)
Valganciclovir Impurity 18 (Valganciclovir Hydrochloride EP Impurity D Hydrochloride)
CAS No.1429306-09-1
Chemical FormulaC14H22N6O5·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Valganciclovir Impurity 37 (Valganciclovir Hydrochloride EP Impurity O) structure
EPO
缬更昔洛韦杂质37 (盐酸缬更昔洛韦EP杂质O)Valganciclovir Impurity 37 (Valganciclovir Hydrochloride EP Impurity O)
Valganciclovir Impurity 37 (Valganciclovir Hydrochloride EP Impurity O)
CAS No.119089-68-8
Chemical FormulaC16H19N5O4
Purity>95%询价On request
10mg25mg50mg100mg
Valganciclovir Impurity 38 (Valganciclovir EP Impurity Q) structure
EPQ
缬更昔洛韦杂质38 (缬更昔洛韦EP杂质Q)Valganciclovir Impurity 38 (Valganciclovir EP Impurity Q)
Valganciclovir Impurity 38 (Valganciclovir EP Impurity Q)
CAS No.1160422-56-9
Chemical FormulaC19H31N7O6
Purity>95%询价On request
10mg25mg50mg100mg
Valganciclovir Impurity 39 (Valganciclovir Hydrochloride EP Impurity R) structure
EPR
缬更昔洛韦杂质39 (盐酸缬更昔洛韦EP杂R)Valganciclovir Impurity 39 (Valganciclovir Hydrochloride EP Impurity R)
Valganciclovir Impurity 39 (Valganciclovir Hydrochloride EP Impurity R)
CAS No.1654737-32-2
Chemical FormulaC14H21ClN6O4
Purity>95%询价On request
10mg25mg50mg100mg
Valganciclovir Impurity 10 (Valganciclovir Hydrochloride EP Impurity T Hydrochloride) structure
EPT
缬更昔洛韦杂质10 (盐酸缬更昔洛韦EP杂质T 盐酸盐)Valganciclovir Impurity 10 (Valganciclovir Hydrochloride EP Impurity T Hydrochloride)
Valganciclovir Impurity 10 (Valganciclovir Hydrochloride EP Impurity T Hydrochloride)
CAS No.1393911-57-3
Chemical FormulaC14H22N6O5·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Valganciclovir Impurity 10  Monomer (Valganciclovir Hydrochloride EP Impurity T) structure
EPT
缬更昔洛韦杂质10 单体 (盐酸缬更昔洛韦EP杂质T)Valganciclovir Impurity 10 Monomer (Valganciclovir Hydrochloride EP Impurity T)
Valganciclovir Impurity 10 Monomer (Valganciclovir Hydrochloride EP Impurity T)
CAS No.1394000-00-0
Chemical FormulaC14H22N6O5
Purity>95%询价On request
10mg25mg50mg100mg
Valganciclovir Monomer-d8 structure
—
盐酸缬更昔洛韦单体-d8Valganciclovir Monomer-d8
Valganciclovir Monomer-d8
CAS No.1132088-63-1
Chemical FormulaC14H14D8N6O5
Purity>95%询价On request
Valganciclovir Monomer structure
—
盐酸缬更昔洛韦单体Valganciclovir Monomer
Valganciclovir Monomer
CAS No.175865-60-8
Chemical FormulaC14H22N6O5
Purity>95%询价On request
10mg25mg50mg100mg
Valganciclovir Impurity 5 structure
5
缬更昔洛韦杂质5Valganciclovir Impurity 5
Valganciclovir Impurity 5
CAS No.88110-89-8
Chemical FormulaC11H15N5O5
Purity>95%询价On request
10mg25mg50mg100mg
Valganciclovir Impurity 6 structure
6
缬更昔洛韦杂质6Valganciclovir Impurity 6
Valganciclovir Impurity 6
CAS No.130914-71-5
Chemical FormulaC19H31N7O6
Purity>95%询价On request
10mg25mg50mg100mg
Valganciclovir Impurity 7 structure
7
缬更昔洛韦杂质7Valganciclovir Impurity 7
Valganciclovir Impurity 7
CAS No.1356932-88-1
Chemical FormulaC15H24N6O6
Purity>95%询价On request
10mg25mg50mg100mg
Valganciclovir Impurity 9 structure
9
缬更昔洛韦杂质9Valganciclovir Impurity 9
Valganciclovir Impurity 9
CAS No.1401562-16-0
Chemical FormulaC15H24N6O5·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Valganciclovir Impurity 9 Monomer structure
9
缬更昔洛韦杂质9 单体Valganciclovir Impurity 9 Monomer
Valganciclovir Impurity 9 Monomer
CAS No.1401661-95-7
Chemical FormulaC15H24N6O5
Purity>95%询价On request
10mg25mg50mg100mg
Valganciclovir Impurity 13 structure
13
缬更昔洛韦杂质13Valganciclovir Impurity 13
Valganciclovir Impurity 13
CAS No.1356353-76-8
Chemical FormulaC15H24N6O6
Purity>95%询价On request
10mg25mg50mg100mg
Valganciclovir Impurity 14 structure
14
缬更昔洛韦杂质14Valganciclovir Impurity 14
Valganciclovir Impurity 14
CAS No.86357-19-9
Chemical FormulaC13H17N5O6
Purity>95%询价On request
10mg25mg50mg100mg
Valganciclovir Impurity 15 structure
15
缬更昔洛韦杂质15Valganciclovir Impurity 15
Valganciclovir Impurity 15
CAS No.6429-68-4
Chemical FormulaC15H19N5O7
Purity>95%询价On request
10mg25mg50mg100mg
Valganciclovir Impurity 17 structure
17
缬更昔洛韦杂质17Valganciclovir Impurity 17
Valganciclovir Impurity 17
CAS No.298197-26-9
Chemical FormulaC13H17N5O6
Purity>95%询价On request
10mg25mg50mg100mg
Valganciclovir Impurity 19 structure
19
缬更昔洛韦杂质19Valganciclovir Impurity 19
Valganciclovir Impurity 19
CAS No.194159-22-3
Chemical FormulaC24H30N6O8
Purity>95%询价On request
10mg25mg50mg100mg
Valganciclovir Impurity 20 structure
20
缬更昔洛韦杂质20Valganciclovir Impurity 20
Valganciclovir Impurity 20
CAS No.1356847-27-2
Chemical FormulaC14H22N6O5
Purity>95%询价On request
10mg25mg50mg100mg
Valganciclovir Impurity 21 structure
21
缬更昔洛韦杂质21Valganciclovir Impurity 21
Valganciclovir Impurity 21
CAS No.1356932-18-7
Chemical FormulaC14H22N6O5
Purity>95%询价On request
10mg25mg50mg100mg
Valganciclovir Impurity 22 structure
22
缬更昔洛韦杂质22Valganciclovir Impurity 22
Valganciclovir Impurity 22
CAS No.1401562-13-7
Chemical FormulaC14H22N6O5·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Valganciclovir Impurity 23 structure
23
缬更昔洛韦杂质23Valganciclovir Impurity 23
Valganciclovir Impurity 23
CAS No.1401661-96-8
Chemical FormulaC29H44N12O10
Purity>95%询价On request
10mg25mg50mg100mg
Valganciclovir Impurity 33 structure
33
缬更昔洛韦杂质33Valganciclovir Impurity 33
Valganciclovir Impurity 33
CAS No.96480-03-4
Chemical FormulaC9H13N5O4
Purity>95%询价On request
10mg25mg50mg100mg
Valganciclovir Impurity 35 structure
35
缬更昔洛韦杂质35Valganciclovir Impurity 35
Valganciclovir Impurity 35
CAS No.1202645-51-9
Chemical FormulaC7H9N5O2
Purity>95%询价On request
10mg25mg50mg100mg
Valganciclovir Impurity 41 structure
41
缬更昔洛韦杂质41Valganciclovir Impurity 41
Valganciclovir Impurity 41
CAS No.175865-62-0
Chemical FormulaC14H22N6O5
Purity>95%询价On request
10mg25mg50mg100mg
Valganciclovir Impurity 41 Hydrochloride structure
41
缬更昔洛韦杂质41 盐酸盐Valganciclovir Impurity 41 Hydrochloride
Valganciclovir Impurity 41 Hydrochloride
CAS No.175865-67-5
Chemical FormulaC14H22N6O5·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Valganciclovir Impurity 44 structure
44
缬更昔洛韦杂质44Valganciclovir Impurity 44
Valganciclovir Impurity 44
CAS No.897937-73-4
Chemical FormulaC19H31N7O6
Purity>95%询价On request
10mg25mg50mg100mg
Valganciclovir Impurity 48 structure
48
缬更昔洛韦杂质48Valganciclovir Impurity 48
Valganciclovir Impurity 48
CAS No.3070439-32-3
Chemical FormulaC7H9N5O2
Purity>95%询价On request
10mg25mg50mg100mg
Valganciclovir Impurity 50 structure
50
缬更昔洛韦杂质50Valganciclovir Impurity 50
Valganciclovir Impurity 50
CAS No.51093-31-3
Chemical FormulaC5H7N5O2
Purity>95%询价On request
10mg25mg50mg100mg
Valganciclovir Impurity 19-d5 structure
19-D5
缬更昔洛韦杂质19-d5Valganciclovir Impurity 19-d5
Valganciclovir Impurity 19-d5
CAS No.1356354-05-6
Chemical FormulaC24H25D5N6O8
Purity>95%询价On request

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

缬更昔洛韦 —— 研究文献与合成路线Valganciclovir — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 缬更昔洛韦 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Valganciclovir. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. A novel liquid chromatography with quadrupole time-of-flight-tandem mass spectroscopy method for ultra-trace level identification and quantification of the genotoxic impurity 2,6-diamino-5-nitropyrimidin-4(3H)-one in valganciclovir hydrochloride
    Ali SM, Moorthy MK, Devanna N · Biomedical chromatography : BMC · 2024 · 被引 5cited 5

合成与制备工艺专利Synthesis & process patents

  1. PROCESS FOR THE PREPARATION OF VALGANCICLOVIR HYDROCHLORIDE
    HASHMI MOHAMMED SALMAN, SHARMA MUKESH KUMAR, KHANDURI CHANDRA HAS · 公开号 WO2011018771WO2011018771 · 2011
  2. PROCESS FOR THE PREPARATION OF AMORPHOUS VALGANCICLOVIR HYDROCHLORIDE
    SETHI MADHURESH KUMAR, RAVAT VIJENDRA SINGH, YERRAMALLA RAJA KRISHNA, VEMULA LAKSHMINARAYANA, et al. · 公开号 WO2011064793WO2011064793 · 2011
  3. PREPARATION OF VALGANCICLOVIR AND ITS SALTS
    KATKAM SRINIVAS, SAGYAM RAJESWAR REDDY, GANTA MADHUSUDHAN REDDY, IRENI BABU, et al. · 公开号 US2011207931US2011207931 · 2011
  4. PREPARATION OF AMORPHOUS VALGANCICLOVIR HYDROCHLORIDE
    NALIVELA VENU, TUMMALA ARJUN KUMAR · 公开号 US2010298564US2010298564 · 2010
  5. PREPARATION OF VALGANCICLOVIR AND ITS SALTS
    PADI PRATAP REDDY, RAMASAMY VIJAYA ANAND, IRENI BABU, KARROTHU SRIHARI BABU, et al. · 公开号 WO2010036904WO2010036904 · 2010

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

缬更昔洛韦 杂质谱研究要点Valganciclovir — impurity profiling notes

下面这些是拿到 缬更昔洛韦 的 32 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 32 impurity entries for Valganciclovir, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances